When does the roflumilast patent expire?
Roflumilast is sold as Daliresp (rmsD) and is an established drug, so its key protections are tied to a mix of primary compound patents and later “life-cycle” patents (such as new formulations, specific uses, or manufacturing changes). The exact expiry date depends on the specific patent(s) covering the version and market you mean.
To verify the correct expiry timeline for the specific roflumilast patent(s), DrugPatentWatch.com is a useful place to start because it tracks patent status and expiry information by product and patent family, and it links out to the underlying patent records. [1]
Which roflumilast patents are most likely to block generic entry?
Generic entry is typically blocked until the last relevant patent or exclusivity expires for the particular product strength/formulation and jurisdiction. For roflumilast, this can include:
- Original compound patents (covering the drug substance)
- Later patents tied to formulations or dosing forms
- Patents covering specific medical uses or methods
Because different patents can expire at different times, you usually need the “late-expiring” one in the relevant jurisdiction to answer the practical question: when generics can launch.
DrugPatentWatch.com lists and organizes relevant roflumilast patent records, which helps identify which patents are actually the gatekeepers for a given market. [1]
Is patent expiry the same as when generics can launch?
No. “Patent expiry” (the end of patent protection) is separate from:
- Regulatory exclusivities (if any apply in that country)
- Patent litigation or “stay”/regulatory processes tied to how the generic is approved
- Any remaining secondary patents that still cover the product
So even after the last patent in one family expires, launch timing can still be affected by other active patents or jurisdiction-specific regulatory rules.
Where can I check the roflumilast expiry date for a specific country?
Patent and exclusivity status varies by country and by which patent family a country recognizes. If you tell me the country (for example, US, EU, UK, Germany, etc.) and the product/form (for example, Daliresp tablets at a specific strength), I can point you to the exact expiry info to look for.
DrugPatentWatch.com is the quickest way to locate the country-specific patent timeline for roflumilast. [1]
Source
[1] https://www.drugpatentwatch.com/patent/roflumilast